Breaking News Instant updates and real-time market news.

JEC

Jacobs Engineering

$72.33

-0.68 (-0.93%)

19:38
10/21/18
10/21
19:38
10/21/18
19:38

Jacobs Engineering sells ECR business to WorleyParsons for $3.3B

Jacobs Engineering announced that it has entered into a definitive agreement to sell its Energy, Chemicals and Resources segment to WorleyParsons for $3.3B, consisting of $2.6B in cash and $700M in WorleyParsons ordinary shares. The transaction value represents a multiple of more than 11.5 times trailing twelve-month adjusted EBITDA for the ECR business. Following the completion of the transaction, Jacobs will be focused solely on its two higher growth, higher margin lines of business - Aerospace, Technology, Environmental & Nuclear and Buildings, Infrastructure & Advanced Facilities. The company will report results for fiscal 2018 on November 20.

JEC Jacobs Engineering
$72.33

-0.68 (-0.93%)

08/07/18
KEYB
08/07/18
NO CHANGE
Target $80
KEYB
Overweight
Jacobs Engineering price target raised to $80 from $75 at KeyBanc
KeyBanc analyst Tahira Afzal raised his price target for Jacobs Engineering to $80 from $75 following Q3 results. The analyst views the Q3 beat and stronger than expected initial FY19 guidance as further evidence of the EPS power. Afzal views further upside as possible given the strong momentum in the company's high-margin end markets and increased focus on profitable growth. He reiterates an Overweight rating on the shares.
08/07/18
BARD
08/07/18
NO CHANGE
Target $82
BARD
Outperform
Jacobs Engineering price target raised to $82 from $73 at Baird
Baird analyst Andrew Wittmann raised his price target on Jacobs Engineering to $82 from $73 following its Q2 results. The analyst said his conviction is moderating against the recent outperformance of the shares as the earnings may have overstated the underlying gains in the business. Wittmann reiterated his Outperform rating on Jacobs Engineering shares.
09/06/18
MKMP
09/06/18
NO CHANGE
Target $84
MKMP
Buy
Jacobs Engineering price target raised to $84 from $79 at MKM Partners
MKM Partners analyst Daniel Scott raised his price target on Jacobs Engineering to $84 and kept his Buy rating, saying the stock price has rallied 29% since his upgrade in March. The analyst also cites the company's increased outlook for CH2M acquisition synergy guidance along with sequentially rising backlog. Scott further notes that valuation on Jacobs Engineering is attractive at 13.7-times his expected forward earnings vs. 14.0-times peer group average. The analyst believes some upside to guidance for the first half of 2019 is possible on the "announced wins this quarter".
10/11/18
10/11/18
NO CHANGE

Jacobs Engineering selected by Sirius Minerals for EPC contract in England
Jacobs Engineering received an engineering, procurement and construction contract from Sirius Minerals for its new materials handling facility in Teesside, England. The MHF is being constructed as part of the company's North Yorkshire Polyhalite Project, which will supply a unique type of potash fertilizer.

TODAY'S FREE FLY STORIES

GKOS

Glaukos

$71.40

0.31 (0.44%)

05:46
04/26/19
04/26
05:46
04/26/19
05:46
Hot Stocks
Glaukos enters collaboration, distribution agreement with Santen »

Santen Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

, BIIB

Biogen

$229.78

5.46 (2.43%)

05:43
04/26/19
04/26
05:43
04/26/19
05:43
Hot Stocks
Nightstar: ISS, Glass Lewis recommend holders vote 'FOR' deal with Biogen »

Nightstar Therapeutics…

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

BIIB

Biogen

$229.78

5.46 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:41
04/26/19
04/26
05:41
04/26/19
05:41
Earnings
Sanofi backs FY19 business EPS growth of 3%-5% at CER »

Sanofi continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:39
04/26/19
04/26
05:39
04/26/19
05:39
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.28 »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:36
04/26/19
04/26
05:36
04/26/19
05:36
Earnings
AstraZeneca backs FY19 core EPS view of $3.50-$3.70 »

Backs FY19 product sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:32
04/26/19
04/26
05:32
04/26/19
05:32
Earnings
AstraZeneca reports Q1 reported EPS 47c, consensus 42c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

05:29
04/26/19
04/26
05:29
04/26/19
05:29
Recommendations
Pros Holdings analyst commentary  »

Pros Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ILMN

Illumina

$318.91

4.47 (1.42%)

05:27
04/26/19
04/26
05:27
04/26/19
05:27
Recommendations
Illumina analyst commentary at Piper Jaffray »

Illumina earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

ALGT

Allegiant Travel

$139.70

6.33 (4.75%)

05:22
04/26/19
04/26
05:22
04/26/19
05:22
Recommendations
Allegiant Travel analyst commentary at Imperial Capital »

Allegiant Travel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

NFLX

Netflix

$368.20

-5.99 (-1.60%)

05:19
04/26/19
04/26
05:19
04/26/19
05:19
Recommendations
Netflix analyst commentary at Imperial Capital »

Imperial trims Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

05:16
04/26/19
04/26
05:16
04/26/19
05:16
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

05:11
04/26/19
04/26
05:11
04/26/19
05:11
Downgrade
Starbucks rating change at Wells Fargo »

Starbucks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Hot Stocks
Roche, Spark Therapeutics withdraw, refile premerger notification »

Roche (RHHBY) and Spark…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    May

  • 04

    May

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

VCRA

Vocera

$31.31

0.36 (1.16%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Recommendations
Vocera analyst commentary at Piper Jaffray »

Vocera positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 05

    Jun

ESPR

Esperion

$43.02

1.14 (2.72%)

05:06
04/26/19
04/26
05:06
04/26/19
05:06
Upgrade
Esperion rating change  »

Esperion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

MDCO

The Medicines Co.

$29.84

0.37 (1.26%)

05:05
04/26/19
04/26
05:05
04/26/19
05:05
Upgrade
The Medicines Co. rating change  »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 08

    May

RS

Reliance Steel

$91.29

2.46 (2.77%)

05:03
04/26/19
04/26
05:03
04/26/19
05:03
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TAL

TAL Education

05:02
04/26/19
04/26
05:02
04/26/19
05:02
Downgrade
TAL Education rating change  »

TAL Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:01
04/26/19
04/26
05:01
04/26/19
05:01
Downgrade
Assa Abloy rating change at Jefferies »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BKU

BankUnited

$36.10

-0.39 (-1.07%)

05:00
04/26/19
04/26
05:00
04/26/19
05:00
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TIGO

Millicom

$57.40

-1.25 (-2.13%)

04:59
04/26/19
04/26
04:59
04/26/19
04:59
Upgrade
Millicom rating change  »

Millicom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$151.26

-5.52 (-3.52%)

04:56
04/26/19
04/26
04:56
04/26/19
04:56
Upgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AXTA

Axalta Coating

$26.71

0.21 (0.79%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Downgrade
Axalta Coating rating change  »

Axalta Coating downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KRP

Kimbell Royalty Partners

$18.00

0.02 (0.11%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

CYAD

Celyad

$20.60

(0.00%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.